Search research articles
Contact Us
Filters
Showing results (391-400 of 404) with videos related to
Page
of 41
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
November 19, 2020
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index
Sebastiano Buti, Melissa Bersanelli, Fabiana Perrone, et al.
Thoracic Cancer
|
February 2, 2021
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study
Alessio Cortellini, Andrea De Giglio, Katia Cannita, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2020
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study
Olga Nigro, Graziella Pinotti, Federica De Galitiis, et al.
Journal of the National Cancer Institute
|
April 12, 2023
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study
Luca Cantini, Francesco Paoloni, Federica Pecci, et al.
Targeted Oncology
|
October 1, 2024
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2<sup>EV</sup> Study
Ondřej Fiala, Francesco Massari, Umberto Basso, et al.
Clinical Genitourinary Cancer
|
April 16, 2023
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)
Matteo Santoni, Francesco Massari, Zin W Myint, et al.
Targeted Oncology
|
June 27, 2023
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study
Matteo Santoni, Francesco Massari, Zin W Myint, et al.
Minerva Urology and Nephrology
|
August 2, 2023
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
Camillo Porta, Aristotelis Bamias, Roubini Zakopoulou, et al.
European Urology Oncology
|
July 22, 2023
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Matteo Santoni, Sebastiano Buti, Zin W Myint, et al.
Eclinicalmedicine
|
July 12, 2023
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study
Melissa Bersanelli, Elena Verzoni, Alessio Cortellini, et al.
Page
of 41
Search research articles
Search
Showing results (391-400 of 404) with videos related to
Sort By:
Page
of 41
European Journal of Cancer (Oxford, England : 1990)
|
November 19, 2020
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index
Sebastiano Buti, Melissa Bersanelli, Fabiana Perrone, et al.
Thoracic Cancer
|
February 2, 2021
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study
Alessio Cortellini, Andrea De Giglio, Katia Cannita, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2020
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study
Olga Nigro, Graziella Pinotti, Federica De Galitiis, et al.
Journal of the National Cancer Institute
|
April 12, 2023
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study
Luca Cantini, Francesco Paoloni, Federica Pecci, et al.
Targeted Oncology
|
October 1, 2024
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2<sup>EV</sup> Study
Ondřej Fiala, Francesco Massari, Umberto Basso, et al.
Clinical Genitourinary Cancer
|
April 16, 2023
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)
Matteo Santoni, Francesco Massari, Zin W Myint, et al.
Targeted Oncology
|
June 27, 2023
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study
Matteo Santoni, Francesco Massari, Zin W Myint, et al.
Minerva Urology and Nephrology
|
August 2, 2023
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
Camillo Porta, Aristotelis Bamias, Roubini Zakopoulou, et al.
European Urology Oncology
|
July 22, 2023
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Matteo Santoni, Sebastiano Buti, Zin W Myint, et al.
Eclinicalmedicine
|
July 12, 2023
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study
Melissa Bersanelli, Elena Verzoni, Alessio Cortellini, et al.
Page
of 41